Navigation Links
JHP Pharmaceuticals Announces Successful Completion of FDA and EMEA GMP Audits
Date:5/10/2010

PARSIPPANY, N.J., May 10 /PRNewswire/ -- JHP Pharmaceuticals' sterile manufacturing site based in Rochester, Michigan completed a successful GMP (Good Manufacturing Practices)/Pre Approval Audit by the U.S. Food and Drug Administration (FDA) drug division (CDER). This audit followed two successful GMP audits in 2009 including an audit by the FDA biologics division (CBER) and an audit by the European Medicines Agency (EMEA), which resulted in a continuance of the certificate of GMP compliance for the manufacturing site.

Stuart Hinchen, co-founder and President of JHP stated, "We are extremely pleased with the results of the recent audits of our Rochester, Michigan sterile injectable manufacturing facility. We understand the importance of compliant quality systems and we work diligently to maintain these systems to the highest global standards."

About JHP Pharmaceuticals, LLC

JHP Pharmaceuticals, headquartered in New Jersey, is a specialty pharmaceutical company that manufactures and sells sterile injectable products for the hospital market segment, and provides contract manufacturing of sterile injectable products for innovator pharmaceutical and biotech organizations. JHP markets 14 branded pharmaceutical products through its national sales and marketing infrastructure and contract manufactures both pharmaceutical and biotechnology products for small and large proprietary pharmaceutical and biotechnology companies. JHP employs more than 330 staff in the USA in its manufacturing, sales & marketing and corporate areas. JHP is a private company wholly owned by JHP Holdings, LLC. For more information, please visit www.jhppharma.com.


'/>"/>
SOURCE JHP Pharmaceuticals, LLC
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Oramed Pharmaceuticals Reports Results in Phase 2b Trial of Oral Insulin Administration to Type 2 Diabetes Patients
2. S*BIO and Onyx Pharmaceuticals Announce Expanded Development Collaboration for JAK2 Inhibitors
3. Amylin Pharmaceuticals to Present at the Deutsche Bank 35th Annual Healthcare Conference
4. Merrimack Pharmaceuticals Promotes William Sullivan to Vice President of Finance
5. Merrimack Pharmaceuticals Recognized for Innovative Talent Management in HR Executive Magazine's ‘Best HR Ideas for 2010' Issue
6. Shire Receives INTUNIV (TM) Paragraph IV Notice Letter From Teva Pharmaceuticals
7. OncoGenex Pharmaceuticals to Webcast Discussion of Financial Results for Fourth Quarter and Fiscal Year 2009
8. Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009
9. OncoGenex Pharmaceuticals to Present at RBC Capital Markets Healthcare Conference
10. APT Pharmaceuticals Completes Enrollment in Phase III for Inhaled Cyclosporine
11. Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2009 Fourth Quarter and Full Year Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2017)... ... April 27, 2017 , ... ... mass flow controllers based on capillary thermal mass flow technology provide exponentially more ... control applications. Over 80% of all industrial processes—such as those involving chemical ...
(Date:4/27/2017)... April 27, 2017  Pendant Biosciences, Inc. (formerly Nanoferix, ... modification and drug delivery technologies, today announced that it ... @ Toronto . ... Pendant Biosciences, noted, "We are excited to become part ... community, and are honored to be the first ...
(Date:4/26/2017)... ... April 26, 2017 , ... Led by ex-FDA ... clinical trials comes to Tampa, San Francisco and Boston in 2017. The ... regulated organizations such as Pfizer Inc., Teva Pharmaceuticals, Advaxis, Inc., Ocular Therapeutix Inc., ...
(Date:4/26/2017)... ... April 26, 2017 , ... ... drive high-level conversations among healthcare industry stakeholders, the discussion surrounding the topic will ... place May 15-18, 2017 in Los Angeles, Calif. Hosted by the Workgroup for ...
Breaking Biology Technology:
(Date:4/6/2017)... -- Forecasts by Product Type (EAC), Biometrics, ... (Transportation & Logistics, Government & Public Sector, Utilities / ... Facility, Nuclear Power), Industrial, Retail, Business Organisation (BFSI), Hospitality ... looking for a definitive report on the $27.9bn Access ... ...
(Date:4/3/2017)... , April 3, 2017  Data ... precision engineering platform, detected a statistically significant ... product prior to treatment and objective response ... the potential to predict whether cancer patients ... to treatment, as well as to improve ...
(Date:3/28/2017)... , March 28, 2017 ... Biometrics), Hardware (Camera, Monitors, Servers, Storage Devices), Software (Video ... and Region - Global Forecast to 2022", published by ... in 2016 and is projected to reach USD 75.64 ... 2017 and 2022. The base year considered for the ...
Breaking Biology News(10 mins):